Bioasas, MB - financials and debts

Company age: 9 y. 10 mo.

Update

Bioasas - Company finances

EUR
2018
From: 2018-01-01
To: 2018-12-31
2019
From: 2019-01-01
To: 2019-12-31
2020
From: 2020-01-01
To: 2020-12-31
2021
From: 2021-01-01
To: 2021-12-31
2022
From: 2022-01-01
To: 2022-12-31
2023
From: 2023-01-01
To: 2023-12-31
2024
From: 2024-01-01
To: 2024-12-31
2025
From: 2025-01-01
To: 2025-12-31
Financial data
Sales revenue 11,471 7,480 - 300 5,320 11,500 18,000 18,980
Profit before tax 2,076 650 -4,478 -3,361 -53 - -556 -413
Net profit 1,950 617 -4,478 -3,361 -53 -301 -556 -413
Equity 1,706 2,323 -2,155 -5,517 0 -5,871 -6,426 -6,839
Liabilities - - - - 9,535 7,680 7,816 7,768
Non-current assets 4,576 3,961 3,345 444 258 88 2 2
Current assets 2,099 5,081 3,187 3,215 3,708 1,721 1,388 927
Total assets 6,675 9,042 6,532 3,659 3,966 1,809 1,390 929
Taxes paid
STI taxes - - - - - 1,106 2,965 3,000
Financial indicators
Revenue change y/y -58.6% -34.8% - - +1673.3% +116.2% +56.5% +5.4%
ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. 29.2% 6.8% -68.6% -91.9% -1.3% -16.6% -40.0% -44.5%
ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. 114.3% 26.6% - - - - - -
Profit margin Net profit margin. Shows the overall profitability of the company. 17.0% 8.2% - -1120.3% -1.0% -2.6% -3.1% -2.2%
EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. 18.1% 8.7% - -1120.3% -1.0% - -3.1% -2.2%
Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. - - - - - - - -
Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. - - - - - - - -

Purchase full financial statements

Profit/Loss, Balance Sheet, Cash Flow, Equity

9.99 € + PVM Buy

See Scoris data in Google Search

Mark Scoris as a favorite source. One click, no registration.

Bioasas - Social security debts

From To Debt, €
2026-07-01 2026-07-31 45.23
2026-06-02 2026-06-30 48.75
2026-05-03 2026-05-31 48.95
2026-04-20 2026-04-30 60.90
2026-04-01 2026-04-19 141.38
2026-03-06 2026-03-31 60.90
2026-03-03 2026-03-05 111.64
2026-02-13 2026-03-02 31.16
2026-02-03 2026-02-12 47.21
2026-01-01 2026-01-31 46.73
2025-12-08 2025-12-31 135.28
2025-12-02 2025-12-07 47.93
2025-11-05 2025-11-30 136.48
2025-11-01 2025-11-04 49.13
2025-10-01 2025-10-31 137.68
2025-09-03 2025-09-30 138.88
2025-09-02 2025-09-02 51.53
2025-08-04 2025-08-31 140.08
2025-08-01 2025-08-03 52.73
2025-07-03 2025-07-31 105.28
2025-07-01 2025-07-02 17.93
2025-06-04 2025-06-30 120.48
2025-06-03 2025-06-03 33.13
2025-05-07 2025-05-31 25.68
2024-10-01 2024-10-31 72.89
2024-09-04 2024-09-30 73.64
2024-07-03 2024-07-31 75.14
2024-06-05 2024-06-30 75.89
2023-07-19 2023-07-31 69.51

Bioasas - VMI tax arrears

From To Overdue, €
2025-04-28 2025-04-30 249.45

VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.

Analysis of the company's financial position

This description was generated by artificial intelligence. Report if inaccurate.
Bioasas, MB (code 304436806) is a Small partnership engaged in intermediation service activities for business support services n.e.c. In 2025, revenue increased to €19.0K, up 5.4% year on year and 65.0% compared with 2023, when revenue was €11.5K. The company remained loss-making, posting net profit of -€413 in 2025 after -€556 in 2024 and -€301 in 2023. Even so, the profit margin improved to -2.2% in 2025 from -3.1% in 2024. The balance sheet stayed under pressure: total assets declined to €929 in 2025 from €1.4K in 2024 and €1.8K in 2023, while equity remained negative at -€6.8K and liabilities were €7.8K. Long-term assets were only €2, so nearly all assets were current. Asset turnover was high at 20.43x, reflecting the very small asset base. The reported ROA was -44.5%, and profitability indicators should be viewed in the context of the company’s negative equity position.